Sleep Disturbances in Survivors of Critical IllnessNCT02059421
Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors
A study testing Cognitive Behavioral Therapy for Insomnia (CBT-I) and Johrei therapy in people with Sleep Disturbances in Survivors of Critical Illness, run by University of Arizona at 1 site in United States.
Trial summary
The purpose of this project is to compare the effectiveness of Johrei therapy (JT) and Cognitive-behavioral Therapy for Insomnia (CBT-I) in the treatment of sleep disturbances in survivors of critical illness. Subjects will be recruited following discharge from the Intensive Care Unit (ICU) and followed for 6 weeks. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Sleep Disturbances in Survivors of Critical Illness
- What is being tested?
- Cognitive Behavioral Therapy for Insomnia (CBT-I) and Johrei therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2014to Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Medical and surgical patients with recent critical illness warranting ICU stay.
Who cannot join
- Patients who are considered too unstable to undergo this investigation by their primary physician
- Patients with severe debilitating neurological disease ( end-stage Alzheimer's, large stroke, or other debilitating neurological disease) that renders patients incapable of providing informed consent
- Pregnancy (All inpatients with recent ICU stay of the childbearing age would have had a pregnancy test while in the hospital).
- Patient's residence is beyond a 20 mile radius from University of Arizona.
- Patient does not have a reliable way of communication such as a cellphone or telephone line.
- Being discharged to a nursing home of skilled nursing facility.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Arizona Medical Center
Tucson, Arizona, 85724
About this study
Official title: Comparative-effectiveness of Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors
The purpose of this project is to compare the effectiveness of Johrei therapy (JT) and Cognitive-behavioral Therapy for Insomnia (CBT-I) in the treatment of sleep disturbances in survivors of critical illness. Subjects will be recruited following discharge from the Intensive Care Unit (ICU) and followed for 6 weeks. All subjects will undergo objective measurements of sleep quality and duration at baseline and at 6 weeks. Objective measurements will be made by portable (home-based) sleep studies and will wear a watch that measures sleep. Subjective measurements will be performed by sleep questionnaires: PSQI, Epworth sleepiness scale, sleep log, and Stanford Sleepiness Scale which will be performed at baseline, 2 and 6 weeks. A blood draw and urine collection will be done at both baseline and 6 weeks.
The central purpose of this proposal is to perform a comparative-effectiveness study of a complementary and alternative approach (Johrei therapy) and CBT-I in the treatment of sleep disturbances in survivors of critical illness. The investigators hypothesize that, in survivors of critical illness, Johrei therapy is superior or comparable to CBT-I in improving sleep quality (Pittsburgh Sleep Quality Index [PSQI] and sleep efficiency [measured by polysomnography]).
Read more
A secondary objective is to compare the effect of Johrei therapy and CBT-I on systemic markers of inflammation and urinary biomarkers of sleep and stress. The investigators hypothesize that, in survivors of critical illness, Johrei therapy is superior or comparable to CBT-I in reducing systemic markers of inflammation and urinary biomarkers of sleep and stress.
A tertiary objective is to determine whether the presence of insomnia or other sleep characteristics is associated with hospital readmissions within 30-days.
Read the detailed description
Survivors of critical illness are known to have poor quality of life. Specifically, post-discharge insomnia symptoms were common and significantly associated with physical quality of life impairment among six-month acute lung injury (ALI) survivors, even after adjustment for post-traumatic stress disorder (PTSD) and depression symptoms. Further studies are needed to validate these results and to characterize sleep disturbance after ALI using sleep-specific metrics. Chronic insomnia impacts 1 in 10 adults and is linked to accidents, decreased quality of life, diminished work productivity, and increased long-term risk for medical and psychiatric diseases such as diabetes and depression. Insomnia and inadequate sleep is an under-recognized problem that ails the investigators society and nearly 8000 preventable deaths per year are attributed to fatigue-related motor vehicle crashes as compared to 13,000 attributable to drunken driving. In a National Gallup poll, it was estimated that nearly 70% of US residents do not get adequate sleep. Inadequate sleep has also been suggested to play a role in the causation and perpetuation of psychiatric disorders and has recently been labeled a carcinogen. Methods to improve sleep and vitality may decrease the effects of inadequate sleep and prevent diseases and deaths due to accidents. Moreover, sleep, or lack thereof, may be a reflection of global stress, disease severity, reveals much about patients' overall well-being and could be associated with hospital readmission.
Cognitive-behavioral therapy for insomnia (CBT-I) is currently considered the gold-standard treatment for insomnia. Recent National Institutes of Health consensus statements and the American Academy of Sleep Medicine's Practice Parameters recommend that cognitive-behavioral therapy for insomnia (CBT-I) be considered the first line treatment for chronic primary insomnia. Growing research also supports the extension of CBT-I for patients with persistent insomnia occurring within the context of medical and psychiatric co-morbidity. Sedative medications for insomnia may be associated with adverse side effects and have even been associated with all-cause mortality. Consequently, other non-pharmacological approaches have been gaining ground as therapeutic approaches for insomnia. Specifically, complementary and alternative forms of therapy such as yoga, mindful meditation, tai chi, Reikei and Johrei therapy have been used to promote sleep quality. Similar to Reikei, Johrei is a nondenominational spiritual practice and complementary and alternative medical therapy that channels the purification energy to a human body through the palm of its practitioner. Such an complementary and alternative treatment has previously been suggested to improve well-being and vitality in human studies. We know that well-being and vitality are facilitated by sleep and that sleep deprivation is associated with reduced well-being and vitality. Moreover, recently we showed that Johrei therapy improves sleep in a murine sleep deprivation model. Whether Johrei therapy achieves an improved sense of well-being through facilitation of sleep in survivors of critical illness is unknown. Specifically, whether or not Johrei therapy is comparable to CBT-I in the management of sleep problems in the survivors of critical illness is largely unknown. The proposed study will address this knowledge gap. If Johrei treatment can improve sleep in survivors of critical illness, patients with reduced vitality due to insufficient sleep (majority of US population), insomnia, and disrupted sleep (sleep apnea) may also benefit from such treatment.
Insomnia subjects, but not good sleepers, show high levels of pro-inflammatory cytokines that are associated with increased risk for heart disease and even mortality. Whether the improvement of sleep through CBT-I or Johrei therapy is mediated by reduction in stress and pro-inflammatory cytokine levels is unknown. The investigators study will address this knowledge gap by measuring circulating levels of cytokines in patients receiving Johrei therapy or CBT-I. Also, recent studies have shown that urinary levels of neurotransmitters may be increased (catecholamines such as epinephrine, norepinephrine, Ɣ-amino butyric acid (GABA)) or decreased (Taurine) in subjects with sleep disturbances. Whether or not CBT-I or other practices aimed at promoting sleep can normalize urinary changes in neurotransmitters is largely unknown.
- JT arm: Johrei treatment will be administered to subjects at the University of Arizona or at the patient's residence for 3 sessions per week lasting 30 minutes each. Two of these sessions will be combined on one day with a 1 hour interval to yield two visits per week. A total of 18 sessions will be administered over the 6 weeks of participation. Therapy will be administered by a senior Johrei administrator who received his training from Reimei Kyokai in Kyoto, Japan. The Johrei will be administered as per all of the principles of Johrei. Before each therapy, the therapist will wash his hands and pray for 1 minute while facing the subject at a distance. The Johrei therapy will be administered without requiring physical contact by the placement of the therapist's hands in proximity of the subject (20 cms). Johrei therapy is a complementary and alternative form of therapy that originated in Japan, like Reiki therapy. Johrei therapy is a non-invasive bio-energy healing practice that is delivered by the outstretched hand of a Johrei practitioner (http://www.johrei-institute.org/aboutus.htm). Similar to Reiki, Johrei is a nondenominational spiritual practice and complementary and alternative medical therapy that channels the purification energy to a human body through the palm of its practitioner but without requiring physical touch. Such a complementary and alternative treatment has previously been suggested to improve well-being and vitality in human studies. We know that well-being and vitality are facilitated by sleep and that sleep deprivation is associated with reduced well-being and vitality. Moreover, recently we showed that Johrei therapy improves sleep in a murine sleep deprivation model.
- CBT-I arm: Cognitive Behavioral therapy for Insomnia will be administered by a licensed and trained clinical psychologist after completion of initial assessment of the nature of the subjects sleep problems via a HIPAA-compliant encrypted Vsee app in the subject's iPAD. Weekly therapy will be administered in a manner that is tailored to suit the subject's need. A total of 6 sessions with an option of two additional sessions will be administered to help promote sleep. The administrator will go over techniques such as sleep restriction therapy, stimulus control instructions, and sleep hygiene education. Also, in order to prevent relapse, education will be provided regarding the extent to which they comprehend the patient's individual circumstances and critically reviewing the rules for good sleep, which in many instances need to be customized to each subject. All conversations and sessions with patients will take place in a manner designed to ensure privacy. For ensuring fidelity of the CBT-I sessions, 20% of the sessions will be video recorded at random for later review by clinical psychologist.
- Being tested
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Johrei therapy
- Keywords
- Johrei therapy, Sleep, CBT-I, Critical illness
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Behavioral Therapy for Insomnia (CBT-I)Behavioural
- Therapy session administered by a clinical psychologist using web-based video conferencing software.
Therapy sessions will include:
- Sleep restriction therapy
- Stimulus control instructions
- Sleep hygiene education
Johrei therapyOther
- Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.
- Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.
- Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.
- Therapy will be administered without physical contact.
- During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient.
| Study group | Role | What they receive |
|---|---|---|
| Johrei Therapy | Experimental | * 3 sessions per week lasting 30 minutes.
* Daily report of bedtime and wake time.
Baseline:
* Polysomnography
* Actigraphy
* Questionnaires
* Blood draw
* Urine collection
2 weeks:
* Questionnaires
* Actigraphy download
* Sleep log reconciliation
6 weeks:
* Polysomnography
* Actigraphy download
* sleep log reconciliation
* Questionnaires
* Blood draw
* Urine collection Receives: Other: Johrei therapy |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Active comparator | * 1 session per week for a total of 6 weeks with the option of 2 additional sessions.
* Daily report of bedtime and wake time.
Baseline:
* Polysomnography
* Actigraphy
* Questionnaires
* Blood draw
* Urine collection
2 weeks:
* Questionnaires
* Actigraphy download
* Sleep log reconciliation
6 weeks:
* Polysomnography
* Actigraphy download
* sleep log reconciliation
* Questionnaires
* Blood draw
* Urine collection Receives: Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pittsburgh Sleep Quality Index (PSQI) (CBT-I, Johrei therapy)
Used to measure sleep quality
Measured: 2 weeks
Polysomnography (CBT-I, Johrei therapy)
Used to measure sleep efficiency
Measured: 6 weeks
Pittsburgh Sleep Quality Index (PSQI) (CBT-I, Johrei therapy)
Used to measure sleep quality.
Measured: 6 weeks
Secondary outcomes (9)
Actigraphy (CBT-I, Johrei therapy)
Objectively measures periods of quiescence that could be inferred to be sleep.
Measured: Baseline, 2 weeks, 6 weeks
Epworth Sleepiness Scale (ESS) (CBT-I, Johrei therapy)
A measure of sleepiness
Measured: Baseline, 2 weeks, 6 weeks
Sleep Log (CBT-I, Johrei therapy)
Used to record bedtimes, wake times, and naps and will then be reconciled with actigraphy downloads.
Measured: Baseline, 2 weeks, 6 weeks
Stanford Sleepiness Scale (SSS) (CBT-I, Johrei therapy)
Measure of Alertness at different times during the day.
Measured: Baseline, 2 weeks, 6 weeks
Post Traumatic Stress Disorder (PTSD) Checklist (CBT-I, Johrei therapy)
Measures response to stressful life experiences.
Measured: Baseline, 2 weeks, 6 weeks
PROMIS Sleep Related Impairment (CBT-I, Johrei therapy)
Measures sleep impairment
Measured: Baseline, 2 weeks, 6 weeks
PROMIS Sleep Disturbance (CBT-I, Johrei therapy)
Measures sleep disturbance
Measured: Baseline, 2 weeks, 6 weeks
Rand 36 Item SF Health Survey Instrument (CBT-I, Johrei therapy)
Measures general health.
Measured: 6 weeks
Cytokines and Neurotransmitters (CBT-I, Johrei therapy)
Measures circulating levels of cytokines and neurotransmitters through blood and urine collection.
Measured: Baseline, 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2014 (estimated)
- Study startJan 2014
- Primary completionJun 2023
- Study completionJun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sleep Disturbances in Survivors of Critical IllnessStudies of the same condition, open and under way.
- More trials run by University of ArizonaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Arizona
- Sponsor type
- University, hospital or other
- Collaborators
- The Johrei Institute
- Responsible party
- Sponsor
- Investigators
- Sairam Parthasarathy, MD, Principal investigator, University of Arizona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02059421
- Sponsor's protocol ID
- 8674
- Other IDs
- The Johrei Institute
- Status last verified
- Apr 2025
- First submitted
- 6 Feb 2014
- Last updated
- 16 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No: There is no plan to share IPD information.
Publications
Buzzetti RA, Hinojosa-Kurtzberg M, Shea TJ, Ibuki Y, Sirakis G, Parthasarathy S. Effect of Johrei therapy on sleep in a murine model. Explore (NY). 2013 Mar-Apr;9(2):100-5. doi: 10.1016/j.explore.2012.12.004.
PubMed 23452712
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative-effectiveness of Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors
- ClinicalTrials.gov ID
- NCT02059421
- Acronym / sponsor ID
- 8674
- Keywords
- Johrei therapy, Sleep, CBT-I, Critical illness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University of ArizonaUniversity, hospital or other
- Collaborators
- The Johrei Institute
- Study start
- Jan 2014
- Primary completion
- Jun 2023 (actual)
- Study completion
- Jun 2023 (actual)
- First posted
- 11 Feb 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this project is to compare the effectiveness of Johrei therapy (JT) and Cognitive-behavioral Therapy for Insomnia (CBT-I) in the treatment of sleep disturbances in survivors of critical illness. Subjects will be recruited following discharge from the Intensive Care Unit (ICU) and followed for 6 weeks. All subjects will undergo objective measurements of sleep quality and duration at baseline and at 6 weeks. Objective measurements will be made by portable (home-based) sleep studies and will wear a watch that measures sleep. Subjective measurements will be performed by sleep questionnaires: PSQI, Epworth sleepiness scale, sleep log, and Stanford Sleepiness Scale which will be performed at baseline, 2 and 6 weeks. A blood draw and urine collection will be done at both baseline and 6 weeks.
The central purpose of this proposal is to perform a comparative-effectiveness study of a complementary and alternative approach (Johrei therapy) and CBT-I in the treatment of sleep disturbances in survivors of critical illness. The investigators hypothesize that, in survivors of critical illness, Johrei therapy is superior or comparable to CBT-I in improving sleep quality (Pittsburgh Sleep Quality Index [PSQI] and sleep efficiency [measured by polysomnography]).
A secondary objective is to compare the effect of Johrei therapy and CBT-I on systemic markers of inflammation and urinary biomarkers of sleep and stress. The investigators hypothesize that, in survivors of critical illness, Johrei therapy is superior or comparable to CBT-I in reducing systemic markers of inflammation and urinary biomarkers of sleep and stress.
A tertiary objective is to determine whether the presence of insomnia or other sleep characteristics is associated with hospital readmissions within 30-days.
Detailed description
Survivors of critical illness are known to have poor quality of life. Specifically, post-discharge insomnia symptoms were common and significantly associated with physical quality of life impairment among six-month acute lung injury (ALI) survivors, even after adjustment for post-traumatic stress disorder (PTSD) and depression symptoms. Further studies are needed to validate these results and to characterize sleep disturbance after ALI using sleep-specific metrics. Chronic insomnia impacts 1 in 10 adults and is linked to accidents, decreased quality of life, diminished work productivity, and increased long-term risk for medical and psychiatric diseases such as diabetes and depression. Insomnia and inadequate sleep is an under-recognized problem that ails the investigators society and nearly 8000 preventable deaths per year are attributed to fatigue-related motor vehicle crashes as compared to 13,000 attributable to drunken driving. In a National Gallup poll, it was estimated that nearly 70% of US residents do not get adequate sleep. Inadequate sleep has also been suggested to play a role in the causation and perpetuation of psychiatric disorders and has recently been labeled a carcinogen. Methods to improve sleep and vitality may decrease the effects of inadequate sleep and prevent diseases and deaths due to accidents. Moreover, sleep, or lack thereof, may be a reflection of global stress, disease severity, reveals much about patients' overall well-being and could be associated with hospital readmission.
Cognitive-behavioral therapy for insomnia (CBT-I) is currently considered the gold-standard treatment for insomnia. Recent National Institutes of Health consensus statements and the American Academy of Sleep Medicine's Practice Parameters recommend that cognitive-behavioral therapy for insomnia (CBT-I) be considered the first line treatment for chronic primary insomnia. Growing research also supports the extension of CBT-I for patients with persistent insomnia occurring within the context of medical and psychiatric co-morbidity. Sedative medications for insomnia may be associated with adverse side effects and have even been associated with all-cause mortality. Consequently, other non-pharmacological approaches have been gaining ground as therapeutic approaches for insomnia. Specifically, complementary and alternative forms of therapy such as yoga, mindful meditation, tai chi, Reikei and Johrei therapy have been used to promote sleep quality. Similar to Reikei, Johrei is a nondenominational spiritual practice and complementary and alternative medical therapy that channels the purification energy to a human body through the palm of its practitioner. Such an complementary and alternative treatment has previously been suggested to improve well-being and vitality in human studies. We know that well-being and vitality are facilitated by sleep and that sleep deprivation is associated with reduced well-being and vitality. Moreover, recently we showed that Johrei therapy improves sleep in a murine sleep deprivation model. Whether Johrei therapy achieves an improved sense of well-being through facilitation of sleep in survivors of critical illness is unknown. Specifically, whether or not Johrei therapy is comparable to CBT-I in the management of sleep problems in the survivors of critical illness is largely unknown. The proposed study will address this knowledge gap. If Johrei treatment can improve sleep in survivors of critical illness, patients with reduced vitality due to insufficient sleep (majority of US population), insomnia, and disrupted sleep (sleep apnea) may also benefit from such treatment.
Insomnia subjects, but not good sleepers, show high levels of pro-inflammatory cytokines that are associated with increased risk for heart disease and even mortality. Whether the improvement of sleep through CBT-I or Johrei therapy is mediated by reduction in stress and pro-inflammatory cytokine levels is unknown. The investigators study will address this knowledge gap by measuring circulating levels of cytokines in patients receiving Johrei therapy or CBT-I. Also, recent studies have shown that urinary levels of neurotransmitters may be increased (catecholamines such as epinephrine, norepinephrine, Ɣ-amino butyric acid (GABA)) or decreased (Taurine) in subjects with sleep disturbances. Whether or not CBT-I or other practices aimed at promoting sleep can normalize urinary changes in neurotransmitters is largely unknown.
- JT arm: Johrei treatment will be administered to subjects at the University of Arizona or at the patient's residence for 3 sessions per week lasting 30 minutes each. Two of these sessions will be combined on one day with a 1 hour interval to yield two visits per week. A total of 18 sessions will be administered over the 6 weeks of participation. Therapy will be administered by a senior Johrei administrator who received his training from Reimei Kyokai in Kyoto, Japan. The Johrei will be administered as per all of the principles of Johrei. Before each therapy, the therapist will wash his hands and pray for 1 minute while facing the subject at a distance. The Johrei therapy will be administered without requiring physical contact by the placement of the therapist's hands in proximity of the subject (20 cms). Johrei therapy is a complementary and alternative form of therapy that originated in Japan, like Reiki therapy. Johrei therapy is a non-invasive bio-energy healing practice that is delivered by the outstretched hand of a Johrei practitioner (http://www.johrei-institute.org/aboutus.htm). Similar to Reiki, Johrei is a nondenominational spiritual practice and complementary and alternative medical therapy that channels the purification energy to a human body through the palm of its practitioner but without requiring physical touch. Such a complementary and alternative treatment has previously been suggested to improve well-being and vitality in human studies. We know that well-being and vitality are facilitated by sleep and that sleep deprivation is associated with reduced well-being and vitality. Moreover, recently we showed that Johrei therapy improves sleep in a murine sleep deprivation model.
- CBT-I arm: Cognitive Behavioral therapy for Insomnia will be administered by a licensed and trained clinical psychologist after completion of initial assessment of the nature of the subjects sleep problems via a HIPAA-compliant encrypted Vsee app in the subject's iPAD. Weekly therapy will be administered in a manner that is tailored to suit the subject's need. A total of 6 sessions with an option of two additional sessions will be administered to help promote sleep. The administrator will go over techniques such as sleep restriction therapy, stimulus control instructions, and sleep hygiene education. Also, in order to prevent relapse, education will be provided regarding the extent to which they comprehend the patient's individual circumstances and critically reviewing the rules for good sleep, which in many instances need to be customized to each subject. All conversations and sessions with patients will take place in a manner designed to ensure privacy. For ensuring fidelity of the CBT-I sessions, 20% of the sessions will be video recorded at random for later review by clinical psychologist.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Johrei Therapy | Experimental | Other: Johrei therapy* 3 sessions per week lasting 30 minutes. * Daily report of bedtime and wake time. Baseline: * Polysomnography * Actigraphy * Questionnaires * Blood draw * Urine collection 2 weeks: * Questionnaires * Actigraphy download * Sleep log reconciliation 6 weeks: * Polysomnography * Actigraphy download * sleep log reconciliation * Questionnaires * Blood draw * Urine collection |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Active comparator | Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)* 1 session per week for a total of 6 weeks with the option of 2 additional sessions. * Daily report of bedtime and wake time. Baseline: * Polysomnography * Actigraphy * Questionnaires * Blood draw * Urine collection 2 weeks: * Questionnaires * Actigraphy download * Sleep log reconciliation 6 weeks: * Polysomnography * Actigraphy download * sleep log reconciliation * Questionnaires * Blood draw * Urine collection |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Medical and surgical patients with recent critical illness warranting ICU stay.
Key exclusion criteria (6 listed)
- Patients who are considered too unstable to undergo this investigation by their primary physician
- Patients with severe debilitating neurological disease ( end-stage Alzheimer's, large stroke, or other debilitating neurological disease) that renders patients incapable of providing informed consent
- Pregnancy (All inpatients with recent ICU stay of the childbearing age would have had a pregnancy test while in the hospital).
- Patient's residence is beyond a 20 mile radius from University of Arizona.
- Patient does not have a reliable way of communication such as a cellphone or telephone line.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Behavioral Therapy for Insomnia (CBT-I)- Therapy session administered by a clinical psychologist using web-based video conferencing software. Therapy sessions will include: * Sleep restriction therapy * Stimulus control instructions * Sleep hygiene education | Behavioural | Cognitive Behavioral Therapy for Insomnia (CBT-I) |
| Johrei therapy* Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence. * Therapy sessions will consist of 3 sessions per week lasting 30 minutes each. * Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance. * Therapy will be administered without physical contact. * During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient. | Other | Johrei Therapy |
Primary outcome
Pittsburgh Sleep Quality Index (PSQI) (CBT-I, Johrei therapy)
Time frame: 2 weeks
Used to measure sleep quality
Polysomnography (CBT-I, Johrei therapy)
Time frame: 6 weeks
Used to measure sleep efficiency
Pittsburgh Sleep Quality Index (PSQI) (CBT-I, Johrei therapy)
Time frame: 6 weeks
Used to measure sleep quality.
9 secondary outcomes
Actigraphy (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
Epworth Sleepiness Scale (ESS) (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
Sleep Log (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
Stanford Sleepiness Scale (SSS) (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
Post Traumatic Stress Disorder (PTSD) Checklist (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
PROMIS Sleep Related Impairment (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
PROMIS Sleep Disturbance (CBT-I, Johrei therapy)
Time frame: Baseline, 2 weeks, 6 weeks
Rand 36 Item SF Health Survey Instrument (CBT-I, Johrei therapy)
Time frame: 6 weeks
Cytokines and Neurotransmitters (CBT-I, Johrei therapy)
Time frame: Baseline, 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2025.
- Background: PubMed 23452712Buzzetti RA, Hinojosa-Kurtzberg M, Shea TJ, Ibuki Y, Sirakis G, Parthasarathy S. Effect of Johrei therapy on sleep in a murine model. Explore (NY). 2013 Mar-Apr;9(2):100-5. doi: 10.1016/j.explore.2012.12.004.
- Individual participant dataSharing planned: No. There is no plan to share IPD information.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sairam Parthasarathy, MD principal investigator
University of Arizona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Behavioral Therapy for Insomnia (CBT-I) and Johrei therapy in people with Sleep Disturbances in Survivors of Critical Illness, run by University of Arizona at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pittsburgh Sleep Quality Index (PSQI) (CBT-I, Johrei therapy) (time frame: 2 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02059421, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2025.